Target intelligence / Profile preview

Oculocutaneous albinism II protein (OCA2)

Target
OCA2
Molecular classification
Transporter (putative), Solute carrier-like protein, Melanosomal membrane protein, Ion channel component (anion channel; see below)
01

Overview

Oculocutaneous albinism II protein (OCA2), also known as P protein or pink-eyed dilution protein homolog, is an integral membrane protein predominantly found in the melanosomal membrane of pigment-producing cells (melanocytes) and the retinal pigment epithelium[1][2][3][5]. OCA2 is predicted to function as a transporter—possibly a Na^+/dicarboxylate symporter or as part of a chloride channel—regulating the ionic environment and pH inside melanosomes to optimize melanin biosynthesis[1][3]. Defects or genetic mutations in OCA2 cause type II oculocutaneous albinism, the most common form of genetically inherited albinism, by impairing melanosome maturation, reducing melanin content, and leading to hypopigmentation of the skin, hair, and eyes as well as vision problems[1][3][4][5]. The protein contains twelve transmembrane helices and functions in the trafficking of other melanosomal proteins, likely through dileucine-based cytoplasmic motifs important for targeting to melanosomes and/or lysosomes[1][2][4]. OCA2 is not a primary therapeutic target nor does it have drugs known to directly interact with it, but mutation testing is a key diagnostic and prognostic biomarker in relevant pigmentation disorders[5].

Other names
P proteinPink-eyed dilution protein homologMelanocyte-specific transporter proteinEye color 2OCA2D15S12SLC13B1PEDSHEP1BOCABEY, BEY1, BEY2EYCL, EYCL2, EYCL3, HCL3
02

Mechanism of action

Not targeted by therapeutic drugs; Genetic mutations affect pigment biosynthesis by disrupting ion transport/chloride conductance[1][3]

03

Biological functions

Regulation of melanosomal pHMelanin biosynthesis supportChloride ion conductance across melanosomal membraneMelanosomal protein trafficking
04

Disease associations

Oculocutaneous albinism type IIPigmentation disorders
05

Safety considerations

Not a common direct therapeutic target; no known pharmacological concernsMutations lead to hypopigmentation and visual defects
06

Biomarkers

OCA2 mutation status (biomarker for oculocutaneous albinism II diagnosis and risk)

Beyond the preview

Go deeper on Oculocutaneous albinism II protein (OCA2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oculocutaneous albinism II protein (OCA2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call